In a publication in Molecular Pharmaceutics, researchers from Fudan University Shanghai Cancer Center China present the design and construction of a positron emission tomography-computed tomography (PET-CT) molecular imaging probe that accurately targets PRMT5, enabling real-time dynamic visualization and quantitative detection of PRMT5 expression levels.
Janux Therapeutics Inc. has nominated a development candidate under its collaboration and exclusive worldwide license agreement with Bristol Myers Squibb Co. (BMS). The milestone was achieved following the identification of a tumor-activated therapeutic, utilizing Janux’s TRACTr (Tumor Activated T Cell Engager) platform, targeting an undisclosed solid tumor antigen expressed across several human cancer types. The milestone triggers a payment to Janux.
Protein arginine methyltransferase 1 (PRMT1) is a key enzyme that catalyzes post-translational arginine methylation, thereby regulating diverse cellular processes, including gene transcription, RNA splicing, signal transduction, and DNA damage repair. As a central epigenetic and signaling regulator, PRMT1 plays a critical role in coordinating cellular proliferation, differentiation, and survival.
Frontier Medicines Corp. has granted LG Chem Ltd. an exclusive worldwide license to develop and commercialize FMC-220, a covalent p53 Y220C activator, outside of Greater China. Frontier retains ownership and full control in Greater China.
Researchers from the University of Naples Federico II (Italy) and collaborating institutions reportedd the design of a next-generation mRNA vaccine that leverages a phylogenetically informed consensus receptor binding domain heterotrimers representing the major variant lineages.
Ernexa Therapeutics Inc. is advancing its lead program, ERNA-101, toward an IND submission in the third quarter of this year and the initiation of a first-in-human trial in the fourth quarter for the treatment of platinum-resistant ovarian cancer.
At the World Vaccine Congress this week, Longhorn Vaccines & Diagnostics LLC presented the preclinical characterization of LHNVD-501, a half-life-extended, humanized IgG monoclonal antibody (mAb) targeting peptidoglycan (PGN). PGN is a conserved structural component shared across bacterial species and an upstream driver of sepsis, as well as metabolic disease, autoimmune disorders and neurodegeneration.
Fosun Pharmaceutical (Group) Co. Ltd. has received the approval from China’s National Medical Products Administration (NMPA) to initiate a clinical trial of FXB-0871 (TEV-56278) for the treatment of locally advanced or metastatic solid tumors.
A new pan-cancer study has uncovered a shared vulnerability across multiple aggressive cancers and sheds light on the role that BRCA1-associated protein 1 (BAP1) plays in recognizing DNA damage. Researchers from Duke-National University of Singapore (NUS) Medical School in Singapore discovered that the loss of BAP1 – a mutation found in mesothelioma, cholangiocarcinoma, renal cell carcinoma and uveal melanoma – creates a specific defect in how cancer cells recognize and repair DNA damage.
RSS
